BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hyvönen M, Enbäck J, Huhtala T, Lammi J, Sihto H, Weisell J, Joensuu H, Rosenthal-Aizman K, El-Andaloussi S, Langel U, Närvänen A, Bergers G, Laakkonen P. Novel target for peptide-based imaging and treatment of brain tumors. Mol Cancer Ther 2014;13:996-1007. [PMID: 24493698 DOI: 10.1158/1535-7163.MCT-13-0684] [Cited by in Crossref: 34] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Charmsaz S, Doherty B, Cocchiglia S, Varešlija D, Marino A, Cosgrove N, Marques R, Priedigkeit N, Purcell S, Bane F, Bolger J, Byrne C, O'Halloran PJ, Brett F, Sheehan K, Brennan K, Hopkins AM, Keelan S, Jagust P, Madden S, Martinelli C, Battaglini M, Oesterreich S, Lee AV, Ciofani G, Hill ADK, Young LS. ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasis. BMC Med 2020;18:349. [PMID: 33208158 DOI: 10.1186/s12916-020-01806-4] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Tang Z, Shen Q, Xie H, Zhou X, Li J, Feng J, Liu H, Wang W, Zhang S, Ni S. Elevated expression of FABP3 and FABP4 cooperatively correlates with poor prognosis in non-small cell lung cancer (NSCLC). Oncotarget 2016;7:46253-62. [PMID: 27323829 DOI: 10.18632/oncotarget.10086] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 10.5] [Reference Citation Analysis]
3 Guidotti G, Brambilla L, Rossi D. Exploring Novel Molecular Targets for the Treatment of High-Grade Astrocytomas Using Peptide Therapeutics: An Overview. Cells 2020;9:E490. [PMID: 32093304 DOI: 10.3390/cells9020490] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Zorko M, Langel Ü. Cell-Penetrating Peptides. Methods Mol Biol 2022;2383:3-32. [PMID: 34766279 DOI: 10.1007/978-1-0716-1752-6_1] [Reference Citation Analysis]
5 Langel Ü. Classes and Applications of Cell-Penetrating Peptides. CPP, Cell-Penetrating Peptides. Singapore: Springer; 2019. pp. 29-82. [DOI: 10.1007/978-981-13-8747-0_2] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Ayo A, Figueras E, Schachtsiek T, Budak M, Sewald N, Laakkonen P. Tumor-Targeting Peptides: The Functional Screen of Glioblastoma Homing Peptides to the Target Protein FABP3 (MDGI). Cancers (Basel) 2020;12:E1836. [PMID: 32650473 DOI: 10.3390/cancers12071836] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Zorko M, Jones S, Langel Ü. Cell-penetrating peptides in protein mimicry and cancer therapeutics. Adv Drug Deliv Rev 2021;180:114044. [PMID: 34774552 DOI: 10.1016/j.addr.2021.114044] [Reference Citation Analysis]
8 van Lith SA, Roodink I, Verhoeff JJ, Mäkinen PI, Lappalainen JP, Ylä-Herttuala S, Raats J, van Wijk E, Roepman R, Letteboer SJ, Verrijp K, Leenders WP. In vivo phage display screening for tumor vascular targets in glioblastoma identifies a llama nanobody against dynactin-1-p150Glued. Oncotarget 2016;7:71594-607. [PMID: 27689404 DOI: 10.18632/oncotarget.12261] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Arcangeli C, Lico C, Baschieri S, Mancuso M. Characterization Of Blood-Brain Barrier Crossing And Tumor Homing Peptides By Molecular Dynamics Simulations. Int J Nanomedicine 2019;14:10123-36. [PMID: 31920308 DOI: 10.2147/IJN.S225793] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
10 Ayo A, Laakkonen P. Peptide-Based Strategies for Targeted Tumor Treatment and Imaging. Pharmaceutics 2021;13:481. [PMID: 33918106 DOI: 10.3390/pharmaceutics13040481] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Seano G, Jain RK. Vessel co-option in glioblastoma: emerging insights and opportunities. Angiogenesis 2020;23:9-16. [PMID: 31679081 DOI: 10.1007/s10456-019-09691-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
12 Mendes M, Sousa JJ, Pais A, Vitorino C. Targeted Theranostic Nanoparticles for Brain Tumor Treatment. Pharmaceutics 2018;10:E181. [PMID: 30304861 DOI: 10.3390/pharmaceutics10040181] [Cited by in Crossref: 46] [Cited by in F6Publishing: 33] [Article Influence: 11.5] [Reference Citation Analysis]
13 Zhang Y, Yuan Z, Shen R, Jiang Y, Xu W, Gu M, Gu X. Identification of biomarkers predicting the chemotherapeutic outcomes of capecitabine and oxaliplatin in patients with gastric cancer. Oncol Lett 2020;20:290. [PMID: 33029206 DOI: 10.3892/ol.2020.12153] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Lico C, Tanno B, Marchetti L, Novelli F, Giardullo P, Arcangeli C, Pazzaglia S, Podda MS, Santi L, Bernini R, Baschieri S, Mancuso M. Tomato Bushy Stunt Virus Nanoparticles as a Platform for Drug Delivery to Shh-Dependent Medulloblastoma. Int J Mol Sci 2021;22:10523. [PMID: 34638864 DOI: 10.3390/ijms221910523] [Reference Citation Analysis]
15 Le Joncour V, Filppu P, Hyvönen M, Holopainen M, Turunen SP, Sihto H, Burghardt I, Joensuu H, Tynninen O, Jääskeläinen J, Weller M, Lehti K, Käkelä R, Laakkonen P. Vulnerability of invasive glioblastoma cells to lysosomal membrane destabilization. EMBO Mol Med 2019;11:e9034. [PMID: 31068339 DOI: 10.15252/emmm.201809034] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]